title: C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab.
abstract: The advent of anti-tumour necrosis factor (TNF) agents to treat inflammatory arthritis has dramatically changed the management of patients in the last few years. Other possible indications for these agents are currently being explored in preliminary studies. However, whether this therapy can be safely and efficaciously applied to other inflammatory disorders requires further case-controlled studies. Since these agents are increasingly used in the last 7 years, there has been the expected emergence of reports on uncommon side effects. The literature on the side effects of anti-TNF agents has focused on infective complications and development of autoantibodies. Reports concerning vasculitis have been contradictory, with TNF blockade being implicated in both the development and treatment of vasculitis. We present the first published report of necrotising crescentic glomerulonephritis associated with positive antineutrophil cytoplasmic antibody in a man receiving treatment with infliximab for rheumatoid arthritis. We discuss the literature and potential causal mechanisms.
authors: Department of Rheumatology, Buckinghamshire Hospitals NHS Trust, High Wycombe, Bucks, UK. dayaanusha@yahoo.com
authors: Dayavathi
authors: D
authors: Ashok
authors: Shirish
authors: S
authors: Dubey
authors: Ian
authors: I
authors: Tomlinson
mesh_terms: D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005921:Glomerulonephritis / Q000139:chemically induced*; D006801:Humans; D000069285:Infliximab; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014657:Vasculitis / Q000139:chemically induced*
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
references: J Rheumatol. 2003 Oct;30(10):2287-91
references: 14528531
references: J Rheumatol. 2003 Dec;30(12):2557-62
references: 14719194
references: Rheumatology (Oxford). 2001 Feb;40(2):178-84
references: 11257154
references: Ann Rheum Dis. 2002 Jul;61(7):667; author reply 667
references: 12079925
references: Br J Rheumatol. 1995 Nov;34(11):1090-1
references: 8542214
references: Ann Intern Med. 1997 Jun 1;126(11):866-73
references: 9163287
references: J Am Soc Nephrol. 2006 Jan;17(1):160-9
references: 16306166
references: Circulation. 2004 Apr 13;109 (14 ):1718-23
references: 15037536
references: J Rheumatol. 2003 Sep;30(9):2064-9
references: 12966617
references: Nephrol Dial Transplant. 2005 Jul;20(7):1400-6
references: 15840673
references: Arch Pathol Lab Med. 1986 Feb;110(2):131-5
references: 3753844
references: Ann Rheum Dis. 2005 Mar;64(3):403-7
references: 15297281